Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy
Abstract Introduction This case describes passenger lymphocyte syndrome (PLS) generating human platelet antigen 1a (HPA‐1a) alloantibodies against the recipient's platelets after liver transplant. Given the rarity of PLS, especially in liver transplant with HPA‐1a alloantibodies, disease course and management options are poorly described. Methods The patient had cirrhosis secondary to nonalcoholic steatohepatitis complicated by hepatocellular carcinoma, encephalopathy, and severe ascites. The model for end‐stage liver disease (MELD) score was 15 at presentation. The patient developed hepatic artery thrombosis after an orthotopic liver transplant and was relisted for transplant with a MELD score of 40. The patient received a hepatitis C virus antibody positive, hepatitis C virus nucleic amplification test positive donor liver on postoperative day (POD) 7 after first transplant. On POD 7 after the second transplant, the patient developed profound thrombocytopenia refractory to platelet infusion. They were found to have serum antibody to HPA‐1a based upon serum platelet alloantibody testing. The donor was later found to be negative for HPA‐1a by genetic testing. However, the patient's native platelets were HPA‐1a positive. The patient was diagnosed with PLS. Results The patient's treatment course included 57 units of platelets transfused, emergency splenectomy, rituximab, plasma exchange, intravenous immunoglobulin (IVIG), eltrombopag, romiplostim, and efgartigimod. Discussion The synergistic effect of efgartigimod with eltrombopag and romiplostim most likely resolved the patient's thrombocytopenia. This case represents a novel use of efgartigimod in the treatment of passenger lymphocyte syndrome following liver transplant..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Transfusion - 64(2024), 4, Seite 755-760 |
| Beteiligte Personen: |
Chase, R. Christopher [VerfasserIn] |
|---|
| Anmerkungen: |
© 2024 AABB |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1111/trf.17748 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY018325297 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY018325297 | ||
| 003 | DE-627 | ||
| 005 | 20240423011800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240423s2024 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/trf.17748 |2 doi | |
| 028 | 5 | 2 | |a 2024-04-22_TRF_2024_64_4.zip.xml |
| 035 | |a (DE-627)WLY018325297 | ||
| 035 | |a (WILEY)TRF17748 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Chase, R. Christopher |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy |
| 264 | 1 | |c 2024 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2024 AABB | ||
| 520 | |a Abstract Introduction This case describes passenger lymphocyte syndrome (PLS) generating human platelet antigen 1a (HPA‐1a) alloantibodies against the recipient's platelets after liver transplant. Given the rarity of PLS, especially in liver transplant with HPA‐1a alloantibodies, disease course and management options are poorly described. Methods The patient had cirrhosis secondary to nonalcoholic steatohepatitis complicated by hepatocellular carcinoma, encephalopathy, and severe ascites. The model for end‐stage liver disease (MELD) score was 15 at presentation. The patient developed hepatic artery thrombosis after an orthotopic liver transplant and was relisted for transplant with a MELD score of 40. The patient received a hepatitis C virus antibody positive, hepatitis C virus nucleic amplification test positive donor liver on postoperative day (POD) 7 after first transplant. On POD 7 after the second transplant, the patient developed profound thrombocytopenia refractory to platelet infusion. They were found to have serum antibody to HPA‐1a based upon serum platelet alloantibody testing. The donor was later found to be negative for HPA‐1a by genetic testing. However, the patient's native platelets were HPA‐1a positive. The patient was diagnosed with PLS. Results The patient's treatment course included 57 units of platelets transfused, emergency splenectomy, rituximab, plasma exchange, intravenous immunoglobulin (IVIG), eltrombopag, romiplostim, and efgartigimod. Discussion The synergistic effect of efgartigimod with eltrombopag and romiplostim most likely resolved the patient's thrombocytopenia. This case represents a novel use of efgartigimod in the treatment of passenger lymphocyte syndrome following liver transplant. | ||
| 700 | 1 | |a Koop, Andree H. |4 aut | |
| 700 | 1 | |a Shaikh, Marwan |4 aut | |
| 700 | 1 | |a Imperial, Robin J. |4 aut | |
| 700 | 1 | |a Harnois, Denise M. |4 aut | |
| 700 | 1 | |a Loo, Nicole M. |4 aut | |
| 700 | 1 | |a O'Brien, Jennifer J. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion |g 64(2024), 4, Seite 755-760 |w (DE-627)WLY013990632 |x 15372995 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2024 |g number:4 |g pages:755-760 |g extent:6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2024 |e 4 |h 755-760 |g 6 | ||